Reviewing Wound Management Technologies (OTCMKTS:WNDM) & Enovis (NYSE:ENOV)

Wound Management Technologies (OTCMKTS:WNDMGet Rating) and Enovis (NYSE:ENOVGet Rating) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Valuation and Earnings

This table compares Wound Management Technologies and Enovis’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Wound Management Technologies $5.84 million 1,043.82 -$600,000.00 N/A N/A
Enovis $3.85 billion 0.82 $71.66 million $1.32 44.25

Enovis has higher revenue and earnings than Wound Management Technologies.


This table compares Wound Management Technologies and Enovis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Wound Management Technologies -10.28% -39.28% -21.49%
Enovis 1.77% 6.35% 3.57%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Wound Management Technologies and Enovis, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Wound Management Technologies 0 0 0 0 N/A
Enovis 0 2 1 0 2.33

Enovis has a consensus price target of $67.00, suggesting a potential upside of 14.69%. Given Enovis’ higher probable upside, analysts clearly believe Enovis is more favorable than Wound Management Technologies.

Volatility & Risk

Wound Management Technologies has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Enovis has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.


Enovis beats Wound Management Technologies on 8 of the 9 factors compared between the two stocks.

About Wound Management Technologies

(Get Rating)

WNDM Medical Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. The company offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as Wound Management Technologies, Inc. and changed its name to WNDM Medical Inc. in April 2017. WNDM Medical Inc. was founded in 1982 and is based in Fort Worth, Texas.

About Enovis

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Receive News & Ratings for Wound Management Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wound Management Technologies and related companies with's FREE daily email newsletter.